Geode Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,469,670
| Closed | -$60.1M | – | 4644 |
|
|
2024
Q2 | $60.1M | Sell |
1,469,670
-404,717
| -22% | -$16.6M | 0.01% | 1229 |
|
|
2024
Q1 | $79.2M | Buy |
1,874,387
+85,085
| +5% | +$3.6M | 0.01% | 1076 |
|
|
2023
Q4 | $75.9M | Buy |
1,789,302
+350,025
| +24% | +$14.8M | 0.01% | 1050 |
|
|
2023
Q3 | $31.4M | Buy |
1,439,277
+93,248
| +7% | +$2.04M | ﹤0.01% | 1532 |
|
|
2023
Q2 | $42.8M | Buy |
1,346,029
+88,109
| +7% | +$2.8M | 0.01% | 1355 |
|
|
2023
Q1 | $30.7M | Buy |
1,257,920
+53,812
| +4% | +$1.31M | ﹤0.01% | 1519 |
|
|
2022
Q4 | $38M | Buy |
1,204,108
+69,847
| +6% | +$2.2M | 0.01% | 1342 |
|
|
2022
Q3 | $32.1M | Buy |
1,134,261
+81,971
| +8% | +$2.32M | ﹤0.01% | 1404 |
|
|
2022
Q2 | $27.8M | Buy |
1,052,290
+126,589
| +14% | +$3.35M | ﹤0.01% | 1519 |
|
|
2022
Q1 | $32.4M | Sell |
925,701
-3,072
| -0.3% | -$108K | ﹤0.01% | 1561 |
|
|
2021
Q4 | $30.1M | Buy |
928,773
+19,658
| +2% | +$637K | ﹤0.01% | 1694 |
|
|
2021
Q3 | $26.8M | Buy |
909,115
+156,688
| +21% | +$4.62M | ﹤0.01% | 1754 |
|
|
2021
Q2 | $19.3M | Buy |
752,427
+308,636
| +70% | +$7.91M | ﹤0.01% | 1990 |
|
|
2021
Q1 | $6.09M | Sell |
443,791
-14,992
| -3% | -$206K | ﹤0.01% | 2686 |
|
|
2020
Q4 | $7.61M | Buy |
+458,783
| New | +$7.61M | ﹤0.01% | 2343 |
|